(4,5-dimethylfuran-2-ylmethyl)-(5-methylfuran-2-ylmethyl)carbamoyl chloride | 637744-56-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: (4,5-dimethylfuran-2-ylmethyl)-(5-methylfuran-2-ylmethyl)carbamoyl chloride
• 英文别名: N-[(4,5-dimethylfuran-2-yl)methyl]-N-[(5-methylfuran-2-yl)methyl]carbamoyl chloride
• CAS: 637744-56-0
• 化学式: C₁₄H₁₆ClNO₃
• 分子量: 281.739
• InChiKey: VWIXVTDWCUYIAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Quinuclidine derivatives and pharmaceutical compositions containing the same
  申请人：Prat Quinones Maria

  公开号：US20060094751A1

  公开（公告）日：2006-05-04

  Carbamates of formula (I) or pharmaceutically acceptable salts thereof, including quaternary ammonium salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of M3 muscarinic receptors.

  本文披露了式（I）的氨甲酰化合物或其药学上可接受的盐，包括式（II）的季铵盐；以及它们的制备过程，包括它们的药物组合物和它们作为M3肌动蛋白受体拮抗剂在治疗中的应用。
• NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
  申请人：Prat Quinones Maria

  公开号：US20090005412A1

  公开（公告）日：2009-01-01

  Carbamates of formula (I) or pharmaceutically acceptable salts thereof, including quaternary ammonium salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of M3 muscarinic receptors.

  公开了化学式（I）的氨基甲酸酯或其药学上可接受的盐，包括化学式（II）的季铵盐；以及它们的制备方法、包含它们的制药组合物以及它们作为M3胆碱能受体拮抗剂在治疗中的应用。
• NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
  申请人：QUINONES Maria PRAT

  公开号：US20090054480A1

  公开（公告）日：2009-02-26

  Carbamates of formula (I) or pharmaceutically acceptable salts thereof, including quaternary ammonium salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of M3 muscarinic receptors.

  本文披露了式(I)的氨基甲酸酯或其药学上可接受的盐，包括式(II)的季铵盐，以及它们的制备过程、包含它们的制药组合物以及它们作为M3胆碱能受体拮抗剂在治疗中的应用。
• QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
  申请人：Almirall Prodesfarma AG

  公开号：EP1515968A2

  公开（公告）日：2005-03-23
• US7435742B2
  申请人：——

  公开号：US7435742B2

  公开（公告）日：2008-10-14